Last updated on March 2018

Specified Drug Use-Results Survey of Regnite


Brief description of study

This study is to investigate the long-term safety and efficacy and the information on the proper use of Regnite under conditions of daily clinical use.

Detailed Study Description

Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite within 52 weeks, follow up on the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or discontinuation.

Clinical Study Identifier: NCT01887613

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )